StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)

Close on Nov 17, 2026Market cap $907.15MP/E –Yield –

Earnings

Aktis Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 29, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$3.90M
EPS, Q3 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Aktis Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 29, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open$3.90M––Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026during market hours$3.40M––Release
Q1 FY2026ended Mar 31, 2026May 11, 2026during market hours$3.20M––Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Aktis Oncology has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Aktis Oncology puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Aktis Oncology filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?